Given the recent approval of a number of bispecific antibodies and several ongoing R&D efforts focused on evaluating the potential of such candidates against various disease indications, this sector of the pharmaceutic industry has garnered significant interest of stakeholder

The USD 16.8 billion (by 2035) financial opportunity within bispecific antibodies market has been analyzed across the following segments:

§  Therapeutic Area

§  Autoimmune Disorders

§  Genetic Disorders

§  Hematological Malignancies

§  Ophthalmic Disorders

§  Skin Cancers

§  Solid Tumors

§  Mechanism of Action

§  Cytokines Retargeting / Neutralization

§  Dual Ligands Blocking

§  Resistance Factors Co-targeting

§  Targeting Tumor Angiogenesis

§  T-Cell Retargeting / Activation

§  Others

§  Target Antigen

§  C5-Albumin

§  CD20 x CD3

§  CD3 x BCMA

§  CD3 x CD19

§  EGFR x cMET

§  EpCAM x CD3

§  Factor IXa x Factor X

§  gp100 x CD3

§  HER2 x HER2

§  PD-1 x CTLA-4

§  PD-L1 x TGFβ

§  TNF-α x HSA

§  VEGF x DLL4

§  VEGF-A x ANG2

§  Antibody Format

§  Asymmetric

§  Fragments

§  Key Players

§  Akeso Biopharma

§  Alexion

§  Amgen

§  Genmab

§  Immunocore

§  Janssen Research & Development

§  Linton Pharm

§  Merck

§  OncXerna Therapeutics

§  Pfizer

§  Roche

§  Taisho Pharmaceutical

§  Zymeworks

§  Key Geographical Regions

§  Asia

§  Europe

§  North America

§  Rest of the World

The Bispecific Antibodies Market, 2023-2035, report features the following companies, which we identified to be key players in this domain:

§  Akeso Biopharma

§  Alphamab Oncology

§  Amgen

§  Merck

§  Regeneron

§  Roche

§  Xencor

Table of Contents

1.      Preface

2.      Executive Summary

3.      Introduction

4.      Market Landscape of Approved and Clinical Therapies

5.      Market Landscape of Preclinical Therapies

6.      Key Insights

7.      Technology Assessment Framework

8.      Big Pharma Players: Benchmarking Analysis

9.      Company Profiles

10.  Partnerships and Collaborations

11.  Contract Services for Bispecific Antibody Therapeutics

12.   Clinical Trial Analysis

13.   Case Study: Regulatory Guidelines for Bispecific Antibodies

14.   Case Study: Promotional / Marketing Strategies

15.   Market Forecast and Opportunity Analysis

16.   SWOT Analysis

17.   Concluding Remarks

18.   Executive insights

19.   Appendix 1: Tabulated data

20.   Appendix 2: List of Companies and Organizations

To view more details on this report, click on the link

https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html

You may also be interested in the following titles:

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415

Ben.johnson@rootsanalysis.com